ORBIMED ADVISORS LLC 13D and 13G filings for Crinetics Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 6:36 pm Sale |
2023-12-31 | 13G | Crinetics Pharmaceuticals, Inc. CRNX |
ORBIMED ADVISORS LLC | 1,667,360 2.500% |
-1,529,516 (-47.84%) |
Filing |
| 2023-02-14 4:12 pm Unchanged |
2022-12-31 | 13G | Crinetics Pharmaceuticals, Inc. CRNX |
ORBIMED ADVISORS LLC | 3,196,876 5.900% |
0 (Unchanged) |
Filing |
| 2022-02-11 4:19 pm Purchase |
2021-12-31 | 13G | Crinetics Pharmaceuticals, Inc. CRNX |
ORBIMED ADVISORS LLC | 3,196,876 6.700% |
443,309 (+16.10%) |
Filing |
| 2021-02-12 4:44 pm Purchase |
2020-12-31 | 13G | Crinetics Pharmaceuticals, Inc. CRNX |
ORBIMED ADVISORS LLC | 2,753,567 8.360% |
714,285 (+35.03%) |
Filing |